Management of Agitation in Elderly Patients with Hepatic Encephalopathy

First-Line Pharmacologic Management

The American Association for the Study of Liver Diseases (AASLD) recommends haloperidol as the preferred first-line agent for agitation in elderly patients with hepatic encephalopathy, starting at 0.5-1 mg orally or subcutaneously, while benzodiazepines should be avoided except for unmanageable agitation requiring small doses of short-acting agents 1, 2
Haloperidol should be started at 0.5-1 mg orally or subcutaneously every 2 hours as needed for agitation, with a maximum dose of 5 mg daily in elderly patients 3
The American Family Physician guidelines suggest monitoring for extrapyramidal symptoms and reducing the dose or switching agents if these occur 4

The AASLD guidelines state that benzodiazepines must be strictly limited or avoided, as sedation should be avoided if possible to prevent precipitating hepatic coma 1, 2
If agitation is truly unmanageable, only short-acting benzodiazepines in small doses should be used 1, 2
Lorazepam carries a 10% risk of paradoxical agitation in elderly patients, and has risks of tolerance, addiction, cognitive impairment, and falls 5

Environmental and behavioral modifications, such as minimizing stimulation and maintaining a quiet environment, should precede or accompany medication 1, 2
Ensuring adequate lighting to reduce confusion, and providing frequent reorientation, are also recommended 3

The AASLD guidelines recommend administering lactulose to reduce ammonia levels, and identifying and correcting precipitating factors such as infection, gastrointestinal bleeding, constipation, electrolyte abnormalities, and medications 1, 2, 6

Frequent mental status checks should be performed, and patients should be transferred to the ICU if consciousness declines from grade I-II to grade III-IV encephalopathy 1, 2
Monitoring for extrapyramidal symptoms with antipsychotics, particularly at higher doses, is also necessary 7, 4

Using benzodiazepines as first-line agents can precipitate hepatic coma and have paradoxical effects in 10% of elderly patients 5, 1, 2
Failing to identify and treat reversible causes like infection, constipation, or medication effects can worsen outcomes 6, 3

Risperidone and olanzapine undergo extensive hepatic metabolism, making them less predictable in hepatic encephalopathy, according to the Journal of the National Comprehensive Cancer Network 8, 9
Quetiapine causes more sedation and orthostatic hypotension, increasing fall risk and potentially worsening encephalopathy, as reported in the Journal of the National Comprehensive Cancer Network 9

The American Association for the Study of Liver Diseases guidelines recommend that haloperidol may be titrated beyond 5 mg in younger patients, as higher doses may be appropriate for managing agitation in patients with liver disease 10
The Journal of Hepatology suggests that identifying and correcting precipitating factors, such as UTI, constipation, electrolyte abnormalities, and other medications that may be worsening encephalopathy, is crucial in managing hepatic encephalopathy 11
The Journal of Hepatology also recommends aggressively treating UTI, as infections are a major precipitant of both hepatic encephalopathy and breakthrough seizures, with the goal of reducing ammonia levels and addressing the underlying liver issues 11